Advertisement

The Future of Neuromodulation

  • Kenneth M. Peters
  • Laura N. Nguyen
  • Larry T. Sirls
Chapter

Abstract

Neuromodulation for the treatment of urological conditions including overactive bladder symptoms has been available for decades but minimal advances have been made to improve efficacy, decrease cost and decrease morbidity. In the past few years, however, many novel devices that take advantage of new technologies have been developed and are currently in testing phases. These new devices address current limitations by using wireless battery charging, external power source technology and minimally invasive percutaneous implantation techniques. In addition to innovative devices, neuromodulation is also expanding for use for broader patient indications and targeting novel nerve targets including the dorsal genital and cavernous nerves.

Keywords

Rechargeable nerve stimulators Implantable nerve stimulators Percutaneous Sacral nerve Pudendal nerve Tibial nerve Cavernous nerve Dorsal genital nerve Axonics neuromodulation system StimGuard StimWave Biowave BlueWind 

References

  1. 1.
    Peters KM, Carey JM, Konstandt DB. Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(4):223–8; discussion 8.  https://doi.org/10.1007/s00192-003-1070-3.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Spinelli M, Weil E, Ostardo E, Del Popolo G, Ruiz-Cerda JL, Kiss G, et al. New tined lead electrode in sacral neuromodulation: experience from a multicentre European study. World J Urol. 2005;23(3):225–9.  https://doi.org/10.1007/s00345-005-0502-8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Borawski KM, Foster RT, Webster GD, Amundsen CL. Predicting implantation with a neuromodulator using two different test stimulation techniques: a prospective randomized study in urge incontinent women. Neurourol Urodyn. 2007;26(1):14–8.  https://doi.org/10.1002/nau.20332.CrossRefGoogle Scholar
  4. 4.
    Leong RK, De Wachter SG, Nieman FH, de Bie RA, van Kerrebroeck PE. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. Neurourol Urodyn. 2011;30(7):1249–52.  https://doi.org/10.1002/nau.20979.CrossRefPubMedGoogle Scholar
  5. 5.
    Amend B, Khalil M, Kessler TM, Sievert KD. How does sacral modulation work best? Placement and programming techniques to maximize efficacy. Curr Urol Rep. 2011;12(5):327–35.  https://doi.org/10.1007/s11934-011-0204-2.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Le NB, Kim JH. Expanding the role of neuromodulation for overactive bladder: new indications and alternatives to delivery. Curr Bladder Dysfunct Rep. 2011;6(1):25–30.  https://doi.org/10.1007/s11884-010-0074-3.CrossRefPubMedGoogle Scholar
  7. 7.
    Alavi K, Chan S, Wise P, Kaiser AM, Sudan R, Bordeianou L. Fecal incontinence: etiology, diagnosis, and management. J Gastrointest Surg. 2015;19(10):1910–21.  https://doi.org/10.1007/s11605-015-2905-1.CrossRefPubMedGoogle Scholar
  8. 8.
    Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet. 1995;346(8983):1124–7.CrossRefGoogle Scholar
  9. 9.
    Cohn JA, Kowalik CG, Kaufman MR, Reynolds WS, Milam DF, Dmochowski RR. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. Expert Rev Med Devices. 2017;14(1):3–14.  https://doi.org/10.1080/17434440.2017.1268913.CrossRefPubMedGoogle Scholar
  10. 10.
    Axonics Modulation Technologies I. Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System. 2016. https://ClinicalTrials.gov/show/NCT02620410.
  11. 11.
    Oerlemans DJ, van Voskuilen AC, Marcelissen T, Weil EH, de Bie RA, Van Kerrebroeck PE. Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime? Neurourol Urodyn. 2011;30(8):1493–6.  https://doi.org/10.1002/nau.21070.CrossRefPubMedGoogle Scholar
  12. 12.
    ’t Hoen LA, Groen J, Scheepe JR, Blok BF. Intermittent sacral neuromodulation for idiopathic urgency urinary incontinence in women. Neurourol Urodyn. 2015.  https://doi.org/10.1002/nau.22938.
  13. 13.
    Fjorback MV, Rijkhoff N, Petersen T, Nohr M, Sinkjaer T. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn. 2006;25(4):349–55.  https://doi.org/10.1002/nau.20170.CrossRefPubMedGoogle Scholar
  14. 14.
    Opisso E, Borau A, Rodriguez A, Hansen J, Rijkhoff NJ. Patient controlled versus automatic stimulation of pudendal nerve afferents to treat neurogenic detrusor overactivity. J Urol. 2008;180(4):1403–8.  https://doi.org/10.1016/j.juro.2008.06.023.CrossRefPubMedGoogle Scholar
  15. 15.
    Nikolavsky D, Killinger K, Boura J, Peters K. Comparison of patients undergoing a two-stage sacral nerve stimulation procedure: is there a cost benefit for a single-stage procedure? Int Urol Nephrol. 2011;43(4):997–1002.  https://doi.org/10.1007/s11255-011-9919-8.CrossRefPubMedGoogle Scholar
  16. 16.
    Baxter C, Kim JH. Contrasting the percutaneous nerve evaluation versus staged implantation in sacral neuromodulation. Curr Urol Rep. 2010;11(5):310–4.  https://doi.org/10.1007/s11934-010-0128-2.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jacobs SA, Lane FL, Osann KE, Noblett KL. Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet. Neurourol Urodyn. 2014;33(5):488–92.  https://doi.org/10.1002/nau.22437.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Spinelli M, Malaguti S, Giardiello G, Lazzeri M, Tarantola J, Van Den Hombergh U. A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data. Neurourol Urodyn. 2005;24(4):305–9.  https://doi.org/10.1002/nau.20118.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Peters KM, Feber KM, Bennett RC. Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn. 2005;24(7):643–7.  https://doi.org/10.1002/nau.20174.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn. 2010;29(7):1267–71.  https://doi.org/10.1002/nau.20823.CrossRefGoogle Scholar
  21. 21.
    Peters KM, Killinger KA, Jaeger C, Chen C. Pilot study exploring chronic pudendal neuromodulation as a treatment option for pain associated with pudendal neuralgia. Low Urin Tract Symptoms. 2015;7(3):138–42.  https://doi.org/10.1111/luts.12066.CrossRefPubMedGoogle Scholar
  22. 22.
    Govier F, Litwiller S, Nitti V, Kreder KJ, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165:1193–8.CrossRefGoogle Scholar
  23. 23.
    van Balken MR, Vandoninck V, Gisolf KW, Vergunst H, Kiemeney LA, Debruyne FM, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol. 2001;166(3):914–8.CrossRefGoogle Scholar
  24. 24.
    Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61.  https://doi.org/10.1016/j.juro.2009.05.045.CrossRefGoogle Scholar
  25. 25.
    Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43.  https://doi.org/10.1016/j.juro.2009.12.036.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183(1):234–40.  https://doi.org/10.1016/j.juro.2009.08.160.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–201.  https://doi.org/10.1016/j.juro.2012.11.175.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. J Urol. 2012;187(1):178–84.  https://doi.org/10.1016/j.juro.2011.09.052.CrossRefPubMedGoogle Scholar
  29. 29.
    Peters KM. Pilot clinical trial on BiowavePTNS (Percutnaeous Tibial Nerve Stimulation) for the treatment of OAB. (Unpublished).Google Scholar
  30. 30.
    van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Implant-driven tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: 12-month follow-up. Neuromodulation. 2006;9(2):163–71.  https://doi.org/10.1111/j.1525-1403.2006.00056.x.CrossRefPubMedGoogle Scholar
  31. 31.
    Janssen DA, Farag F, Heesakkers JP. Urgent-SQ implant in treatment of overactive bladder syndrome: 9-year follow-up study. Neurourol Urodyn. 2013;32(5):472–5.  https://doi.org/10.1002/nau.22322.CrossRefPubMedGoogle Scholar
  32. 32.
    Elneil S, Digesu A, van Breda H, Heesakkers J, Van Kerrebroeck P. Safety and performance of a wireless implantable tibial nerve stimulator device for the treatment of patients with overactive bladder (OAB). Neurourol Urodyn. 2016;35(Suppl 4):S45–S6.  https://doi.org/10.1002/nau.23074.CrossRefGoogle Scholar
  33. 33.
    BlueWind Medical, Rainbow Medical. BlueWind reprieve system for the treatment of PNP. 2014. https://ClinicalTrials.gov/show/NCT02209896.
  34. 34.
    Rainbow Medical, BlueWind Medical. Overactive bladder posterior tibial implantable MIcro STimulator-1. 2017. https://ClinicalTrials.gov/show/NCT03019094.
  35. 35.
    Sirls L, Peters K. A cadaver model describing a novel retrograde approach for percutaneous placement of an implantable tibial nerve stimulation lead. In: International Continence Society Annual Meeting 2016, Tokyo, Japan; 13–16 Sept 2016.Google Scholar
  36. 36.
    Kessler TM, Knuepfer S, De Wachter S, Kozomara M, Sievert K. Tibial neuromodulation: novel chronic implantable device achieves urinary continence in initial cases. In: International Continence Society Annual Meeting 2016, Tokyo, Japan; 13–16 Sept 2016.Google Scholar
  37. 37.
    StimGuard, LLC. CAN-stim compared to PTNS in treatment of urinary urgency incontinence with wireless neuromodulation technology. 2016. https://ClinicalTrials.gov/show/NCT02577302.
  38. 38.
    Thomas GP, Dudding TC, Bradshaw E, Nicholls RJ, Vaizey CJ. A pilot study to compare daily with twice weekly transcutaneous posterior tibial nerve stimulation for faecal incontinence. Color Dis. 2013;15(12):1504–9.  https://doi.org/10.1111/codi.12428.CrossRefGoogle Scholar
  39. 39.
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.CrossRefGoogle Scholar
  40. 40.
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–44.CrossRefGoogle Scholar
  41. 41.
    McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332(7541):589–92.  https://doi.org/10.1136/bmj.332.7541.589.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology. 2001;57(6):1141–4.  https://doi.org/10.1016/s0090-4295(01)00984-0.CrossRefPubMedGoogle Scholar
  43. 43.
    Kucuk EV, Tahra A, Bindayi A, Onol FF. Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments. Andrology. 2016;4(5):952–6.  https://doi.org/10.1111/andr.12237.CrossRefPubMedGoogle Scholar
  44. 44.
    Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14.  https://doi.org/10.1016/j.eururo.2010.02.020.CrossRefPubMedGoogle Scholar
  45. 45.
    Lue TF, Schmidt RA, Tanagho EA. Electrostimulation and penile erection. Urol Int. 1985;40(1):60–4.CrossRefGoogle Scholar
  46. 46.
    Mueller SC, Aboseif S, Fahey MR, Lue TF, Tanagho EA. Spinal anesthesia and electroerection in dogs and monkeys. J Urol. 1989;142(1):171–5.CrossRefGoogle Scholar
  47. 47.
    Martinez-Pineiro L, Brock G, Trigo-Rocha F, Hsu GL, Lue TF, Tanagho EA. Rat model for the study of penile erection: pharmacologic and electrical-stimulation parameters. Eur Urol. 1994;25(1):62–70.CrossRefGoogle Scholar
  48. 48.
    Lue TF, Gleason CA, Brock GB, Carroll PR, Tanagho EA. Intraoperative electrostimulation of the cavernous nerve: technique, results and limitations. J Urol. 1995;154(4):1426–8.CrossRefGoogle Scholar
  49. 49.
    Shafik A. Cavernous nerve stimulation through an extrapelvic subpubic approach: role in penile erection. Eur Urol. 1994;26(1):98–102.CrossRefGoogle Scholar
  50. 50.
    Shafik A. Extrapelvic cavernous nerve stimulation in erectile dysfunction. Human study. Andrologia. 1996;28(3):151–6.CrossRefGoogle Scholar
  51. 51.
    Shafik A, el-Sibai O, Shafik AA. Magnetic stimulation of the cavernous nerve for the treatment of erectile dysfunction in humans. Int J Impot Res. 2000;12(3):137–41; discussion 41–2.CrossRefGoogle Scholar
  52. 52.
    Peters KM. A pilot study of the feasibility of chronic cavernous nerve stimulation to promote regeneration and erectile function. https://ClinicalTrials.gov/show/NCT02006927.
  53. 53.
    Marcelissen T, Van Kerrebroeck P, de Wachter S. Sacral neuromodulation as a treatment for neuropathic clitoral pain after abdominal hysterectomy. Int Urogynecol J. 2010;21(10):1305–7.  https://doi.org/10.1007/s00192-010-1145-x.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Jones CL, Fischer JR, Hernandez SL. Sacral neuromodulation for the treatment of persistent genital arousal disorder. Obstet Gynecol. 2016;128(2):321–3.  https://doi.org/10.1097/AOG.0000000000001452.CrossRefPubMedGoogle Scholar
  55. 55.
    Hill AJ, Paraiso MF. Resolution of chronic vulvar pruritus with replacement of a neuromodulation device. J Minim Invasive Gynecol. 2015;22(5):889–91.  https://doi.org/10.1016/j.jmig.2015.02.020.CrossRefPubMedGoogle Scholar
  56. 56.
    Ramsay LB, Wright J Jr, Fischer JR. Sacral neuromodulation in the treatment of vulvar vestibulitis syndrome. Obstet Gynecol. 2009;114(2 Pt 2):487–9.  https://doi.org/10.1097/AOG.0b013e3181af5f80.CrossRefPubMedGoogle Scholar
  57. 57.
    Krames E, Mousad DG. Spinal cord stimulation reverses pain and diarrheal episodes of irritable bowel syndrome: a case report. Neuromodulation. 2004;7(2):82–8.  https://doi.org/10.1111/j.1094-7159.2004.04011.x.CrossRefPubMedGoogle Scholar
  58. 58.
    Canbaz Kabay S, Kabay S, Mestan E, Cetiner M, Ayas S, Sevim M, et al. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Neurourol Urodyn. 2017;36(1):104–10.  https://doi.org/10.1002/nau.22868.CrossRefPubMedGoogle Scholar
  59. 59.
    Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience. Spinal Cord. 2014;52(3):241–5.  https://doi.org/10.1038/sc.2013.155.CrossRefPubMedGoogle Scholar
  60. 60.
    Wosnitzer MS, Walsh R, Rutman MP. The use of sacral neuromodulation for the treatment of non-obstructive urinary retention secondary to Guillain-Barre syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(9):1145–7.  https://doi.org/10.1007/s00192-009-0826-9.CrossRefPubMedGoogle Scholar
  61. 61.
    Guys JM, Haddad M, Planche D, Torre M, Louis-Borrione C, Breaud J. Sacral neuromodulation for neurogenic bladder dysfunction in children. J Urol. 2004;172(4 Pt 2):1673–6.CrossRefGoogle Scholar
  62. 62.
    Marinkovic SP, Miller B, Hughes S, Marinkovic C, Gillen L. Successful bilateral pudendal neuromodulation to treat male detrusor areflexia following severe pubic symphysis fracture, a case report. BMC Urol. 2015;15:115.  https://doi.org/10.1186/s12894-015-0108-4.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Baron M, Grynberg L, Delcourt C, Cornu JN, Grise P. [Does urinary sacral neuromodulation improve bowel symptoms other than fecal incontinence: a systematic review]. Prog Urol. 2016;26(7):395–400.  https://doi.org/10.1016/j.purol.2016.01.007.
  64. 64.
    Killinger KA, Kangas JR, Wolfert C, Boura JA, Peters KM. Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation. Neurourol Urodyn. 2011;30(1):133–7.  https://doi.org/10.1002/nau.20975.CrossRefPubMedGoogle Scholar
  65. 65.
    van der Wilt AA, van Wunnik BP, Sturkenboom R, Han-Geurts IJ, Melenhorst J, Benninga MA, et al. Sacral neuromodulation in children and adolescents with chronic constipation refractory to conservative treatment. Int J Color Dis. 2016;31(8):1459–66.  https://doi.org/10.1007/s00384-016-2604-8.CrossRefGoogle Scholar
  66. 66.
    Musco S, Serati M, Lombardi G, Lumi E, Parisi AI, Del Popolo G, et al. Percutaneous tibial nerve stimulation improves female sexual function in women with overactive bladder syndrome. J Sex Med. 2016;13(2):238–42.  https://doi.org/10.1016/j.jsxm.2015.12.025.CrossRefPubMedGoogle Scholar
  67. 67.
    Parnell BA, Howard JF Jr, Geller EJ. The effect of sacral neuromodulation on pudendal nerve function and female sexual function. Neurourol Urodyn. 2015;34(5):456–60.  https://doi.org/10.1002/nau.22579.CrossRefPubMedGoogle Scholar
  68. 68.
    Yih JM, Killinger KA, Boura JA, Peters KM. Changes in sexual functioning in women after neuromodulation for voiding dysfunction. J Sex Med. 2013;10(10):2477–83.  https://doi.org/10.1111/jsm.12085.CrossRefPubMedGoogle Scholar
  69. 69.
    Dwyer ME, Vandersteen DR, Hollatz P, Reinberg YE. Sacral neuromodulation for the dysfunctional elimination syndrome: a 10-year single-center experience with 105 consecutive children. Urology. 2014;84(4):911–7.  https://doi.org/10.1016/j.urology.2014.03.059.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Goldman HB, Amundsen CL, Mangel J, Grill J, Bennett M, Gustafson KJ, et al. Dorsal genital nerve stimulation for the treatment of overactive bladder symptoms. Neurourol Urodyn. 2008;27(6):499–503.  https://doi.org/10.1002/nau.20544.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Horvath EE, Yoo PB, Amundsen CL, Webster GD, Grill WM. Conditional and continuous electrical stimulation increase cystometric capacity in persons with spinal cord injury. Neurourol Urodyn. 2010;29(3):401–7.  https://doi.org/10.1002/nau.20766.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Martens FM, Heesakkers JP, Rijkhoff NJ. Minimal invasive electrode implantation for conditional stimulation of the dorsal genital nerve in neurogenic detrusor overactivity. Spinal Cord. 2011;49(4):566–72.  https://doi.org/10.1038/sc.2010.134.CrossRefPubMedGoogle Scholar
  73. 73.
    Opisso E, Borau A, Rijkhoff NJ. Subject-controlled stimulation of dorsal genital nerve to treat neurogenic detrusor overactivity at home. Neurourol Urodyn. 2013;32(7):1004–9.  https://doi.org/10.1002/nau.22359.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    van Breda HM, Farag FF, Martens FM, Heesakkers JP, Rijkhoff NJ. Subject-controlled, on-demand, dorsal genital nerve stimulation to treat urgency urinary incontinence; a pilot. Front Neurosci. 2016;10:24.  https://doi.org/10.3389/fnins.2016.00024.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Grinberg Y, Schiefer MA, Tyler DJ, Gustafson KJ. Fascicular perineurium thickness, size, and position affect model predictions of neural excitation. IEEE Trans Neural Syst Rehabil Eng. 2008;16(6):572–81.  https://doi.org/10.1109/TNSRE.2008.2010348.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Das AK, White MD, Longhurst PA. Sacral nerve stimulation for the management of voiding dysfunction. Rev Urol. 2000;2(1):43–60.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Kenneth M. Peters
    • 1
  • Laura N. Nguyen
    • 1
  • Larry T. Sirls
    • 1
  1. 1.Department of UrologyBeaumont HealthRoyal OakUSA

Personalised recommendations